Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Corroborated by 2 sources from 2 publishers
globalbusiness4h ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, strategic Portfolio Realignment and Market Dynamics - Management is divesting the China immunodiagnostics business to exit a market facing persistent policy-induced headwinds, pricing pressures, and structural requirements for localized manufacturing.